Ponatinib Suppresses the Development of Myeloid and Lymphoid Malignancies Associated With FGFR1 Abnormalities

Leukemia - United Kingdom
doi 10.1038/leu.2012.188
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Del(6q) Abnormalities in Lymphoid Malignancies

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2011English

FGFR1 -Associated Myeloid Neoplasm With Increased Mast Cells

British Journal of Haematology
Hematology
2017English

EZH2 Abnormalities in Lymphoid Malignancies: Underlying Mechanisms and Therapeutic Implications

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2019English

Susceptibility Loci Associated With Specific and Shared Subtypes of Lymphoid Malignancies

PLoS Genetics
EvolutionEcologyGeneticsMolecular BiologyCancer ResearchSystematicsBehavior
2013English

Clinical Impact of the Immunome in Lymphoid Malignancies: The Role of Myeloid-Derived Suppressor Cells

Frontiers in Oncology
Cancer ResearchOncology
2015English

Eruptive Melanocytic Nevi Associated With Ponatinib

JAAD Case Reports
Dermatology
2018English

CDK6 and P16INK4a in Lymphoid Malignancies

Oncotarget
Oncology
2013English

Rechallenge of Ponatinib in Chronic Myeloid Leukaemia After Hepatotoxicity

Hong Kong Medical Journal
Medicine
2019English

Novel Immunotherapies in Lymphoid Malignancies

Nature Reviews Clinical Oncology
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy